Research & Literature

Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping.

Hayashi T, Hirayama F

Blood transfusion = Trasfusione del sangue 2015; (13(3)):380-90 doi:10.2450/2015.0275-14.

Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia.

Curtis BR

British journal of haematology 2015; (171(5)):671-82 doi:10.1111/bjh.13639.

Fetal and neonatal alloimmune thrombocytopenia.

Zdravic D, Yougbare I, Vadasz B, et al.

Seminars in fetal & neonatal medicine 2016; (21(1)):19-27.

Severe bleeding complications other than intracranial hemorrhage in neonatal alloimmune thrombocytopenia: a case series and review of the literature.

Winkelhorst D, Kamphuis MM, de Kloet LC, et al.

Transfusion 2016; (56(5)):1230-5 doi:10.1111/trf.13550.

Sensitive detection of platelet-specific antibodies with a modified MAIPA using biotinylated antibodies and streptavidin-coated beads.

Mörtberg A, Meinke S, Berg P, et al.

Journal of immunological methods 2016; (434()):9-15.

Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort.

Kamphuis MM, Tiller H, van den Akker ES, et al.

Fetal diagnosis and therapy 2017; (41(4)):251-257 doi:10.1159/000448753.

Low-dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity.

Skariah A, Sung N, Salazar Garcia MD, et al.

American journal of reproductive immunology (New York, N.Y. : 1989) 2017; (77(6)) doi:10.1111/aji.12649.

Taking a wider view on fetal/neonatal alloimmune thrombocytopenia.

Bonstein L, Haddad N

Thrombosis research 2017; (151 Suppl 1()):S100-S102 doi:10.1016/S0049-3848(17)30078-6.

Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia.

Vadasz B, Chen P, Yougbaré I, et al.

Genes & diseases 2015; (2(2)):173-185 doi:10.1016/j.gendis.2015.02.003.

Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.

Tiller H, Husebekk A, Ahlen MT, et al.

International journal of women's health 2017; (9()):223-234 doi:10.2147/IJWH.S90753.

Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies.

Winkelhorst D, Oepkes D, Lopriore E

Expert review of hematology 2017; (10(8)):729-737 doi:10.1080/17474086.2017.1346471.

Intracranial hemorrhages in neonates born from 32 weeks of gestation-low frequency of associated fetal and neonatal alloimmune thrombocytopenia: a register-based study.

Refsum E, Håkansson S, Mörtberg A, et al.

Transfusion 2018; (58(1)):223-231 doi:10.1111/trf.14394.

Perinatal Outcome and Long-Term Neurodevelopment after Intracranial Haemorrhage due to Fetal and Neonatal Alloimmune Thrombocytopenia.

Winkelhorst D, Kamphuis MM, Steggerda SJ, et al.

Fetal diagnosis and therapy 2019; (45(3)):184-191 doi:10.1159/000488280.

Implication of antibodies against human leukocyte antigen in simultaneous presentation of fetal and neonatal alloimmune thrombocytopenia and neutropenia.

Gimferrer I, Teramura G, Gallagher M, et al.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2018; (57(6)):773-776 doi:10.1016/j.transci.2018.09.018.

Marked thrombocytopenia in a neonate is associated with anti-HPA-5b, anti-HLA-A31, and anti-HLA-B55 antibodies.

Okubo M, Nishida E, Watanabe A, et al.

Pediatric blood & cancer 2019; (66(3)):e27555 doi:10.1002/pbc.27555.

Management of neonatal thrombocytopenia in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group.

Bertrand G, Blouin L, Boehlen F, et al.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2019; (26(3)):191-197 doi:10.1016/j.arcped.2019.02.006.

Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.

Lieberman L, Greinacher A, Murphy MF, et al.

British journal of haematology 2019; (185(3)):549-562 doi:10.1111/bjh.15813.

Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61.

Regan F, Lees CC, Jones B, et al.

BJOG : an international journal of obstetrics and gynaecology 2019; (126(10)):e173-e185 doi:10.1111/1471-0528.15642.

Postnatal intervention for the treatment of FNAIT: a systematic review.

Baker JM, Shehata N, Bussel J, et al.

Journal of perinatology : official journal of the California Perinatal Association 2019; (39(10)):1329-1339 doi:10.1038/s41372-019-0360-7.

Fetal and neonatal alloimmune thrombocytopenia - The Norwegian management model.

Tiller H, Ahlen MT, Akkök ÇA, Husebekk A

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102711 doi:10.1016/j.transci.2019.102711.

The use of IVIg in fetal and neonatal alloimmune thrombocytopenia- Principles and mechanisms.

Wabnitz H, Khan R, Lazarus AH

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102710 doi:10.1016/j.transci.2019.102710.

Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia.

de Vos TW, Winkelhorst D, de Haas M, et al.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102704 doi:10.1016/j.transci.2019.102704.

A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility.

Ouzegdouh Mammasse Y, Chenet C, Drubay D, et al.

British journal of haematology 2020; (190(5)):787-798 doi:10.1111/bjh.16593.

Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events.

Wienzek-Lischka S, Sawazki A, Ehrhardt H, et al.

Archives of gynecology and obstetrics 2020; (302(2)):355-363 doi:10.1007/s00404-020-05618-y.

Neonatal alloimmune thrombocytopenia due to anti-HPA 5a in a HPA-5a homozygous neonate.

Porta R, Serrano P, Paltrinieri A, et al.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(6)):102880 doi:10.1016/j.transci.2020.102880.

Benefits and Risks of IgG Transplacental Transfer.

Ciobanu AM, Dumitru AE, Gica N, et al.

Diagnostics (Basel, Switzerland) 2020; (10(8)) doi:10.3390/diagnostics10080583.

Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.

Kjeldsen-Kragh J, Bengtsson J

Transfusion medicine reviews 2020; (34(4)):270-276 doi:10.1016/j.tmrv.2020.09.004.

New developments in fetal and neonatal alloimmune thrombocytopenia.

Bussel JB, Vander Haar EL, Berkowitz RL

American journal of obstetrics and gynecology 2021; (225(2)):120-127 doi:10.1016/j.ajog.2021.04.211.

[Management of high-risk pregnancies in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group].

Bertrand G,

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2021; (28(4)):370-374 doi:10.1016/j.tracli.2021.08.349.

Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.

Zhi H, Ahlen MT, Skogen B, et al.

Blood advances 2021; (5(18)):3552-3562 doi:10.1182/bloodadvances.2021004371.

Subamniotic Hemorrhage, a Possible New Presentation of Fetal and Neonatal Alloimmune Thrombocytopenia.

Giesbers S, Bos M, Bulten J, et al.

Fetal diagnosis and therapy 2022; (49(1-2)):60-64 doi:10.1159/000521866.

Cerebral vasculature exhibits dose-dependent sensitivity to thrombocytopenia that is limited to fetal/neonatal life.

Farley AM, Dayton M, Biben C, et al.

Blood 2022; (139(15)):2355-2360 doi:10.1182/blood.2021014094.

Noninvasive Prenatal Testing in Immunohematology-Clinical, Technical and Ethical Considerations.

Kjeldsen-Kragh J, Hellberg Å

Journal of clinical medicine 2022; (11(10)) doi:10.3390/jcm11102877.

Long-term neurodevelopmental outcome in children after antenatal intravenous immune globulin treatment in fetal and neonatal alloimmune thrombocytopenia.

de Vos TW, de Haas M, Oepkes D, et al.

American journal of obstetrics and gynecology 2022; (227(4)):637.e1-637.e9 doi:10.1016/j.ajog.2022.05.063.

Clinical and laboratory predictors of fetal and neonatal alloimmune thrombocytopenia.

Matusiak K, Patriquin CJ, Deniz S, et al.

Transfusion 2022; (62(11)):2213-2222 doi:10.1111/trf.17144.

New Horizons in Fetal and Neonatal Alloimmune Thrombocytopenia.

Barg A, Bonstein L

Seminars in thrombosis and hemostasis 2023; (49(4)):402-408 doi:10.1055/s-0042-1757900.

FNAIT pathogenesis determined by serial analysis of three subsequent pregnancies of a woman with severe fetal and neonatal alloimmune thrombocytopenia (FNAIT) with anti-HPA-4b and anti-HPA-5b alloantibodies in the first sibling.

Kiyokawa T, Mimura K, Nagamine K, et al.

International journal of hematology 2023; (118(1)):146-150 doi:10.1007/s12185-023-03559-1.

Children Newly Diagnosed with Fetal and Neonatal Alloimmune Thrombocytopenia: Neurodevelopmental Outcome at School Age.

de Vos TW, van Zagten M, de Haas M, et al.

The Journal of pediatrics 2023; (258()):113385 doi:10.1016/j.jpeds.2023.02.031.

Pregnant Women at Low Risk of Having a Child with Fetal and Neonatal Alloimmune Thrombocytopenia Do Not Require Treatment with Intravenous Immunoglobulin.

Kjeldsen-Kragh J, Bein G, Tiller H

Journal of clinical medicine 2023; (12(17)) doi:10.3390/jcm12175492.

Immunomodulation of Antibody Glycosylation through the Placental Transfer.

Gao C, Chen Q, Hao X, Wang Q

International journal of molecular sciences 2023; (24(23)) doi:10.3390/ijms242316772.

Severe neonatal thrombocytopenia due to anti-HPA-4b alloantibodies: Third report described in a Caucasian mother.

Petermann R, Bianchi F, Saib L, et al.

Transfusion 2024; (64(6)):1167-1170 doi:10.1111/trf.17863.

An Atypical Case of Neonatal Alloimmune Thrombocytopenia.

Mutluoglu G, De Muynck B, Emonds MP, Van Maerken T

Journal of pediatric hematology/oncology 2025; (47(2)):e125-e127 doi:10.1097/MPH.0000000000002988.

Persistent neonatal alloimmune thrombocytopenia caused by triple anti-HLA-A11, -B3901, and -Cw7 antibodies.

Hatano S, Maeda H, Ichikawa H, et al.

International journal of hematology 2025; (121(6)):866-871 doi:10.1007/s12185-025-03968-4.

Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.

Tiller H, Tiblad E, Baker P, et al.

American journal of perinatology 2025; doi:10.1055/a-2666-5642.

HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins.

Oosterhoff JJ, Stam W, van Brummelen SR, et al.

Blood 2025; (146(18)):2189-2202 doi:10.1182/blood.2025029618.

Non-invasive fetal HPA genotyping by UMI-NGS: a robust method for antenatal diagnosis including 48 fetal DNA markers.

Bertrand G, Levallois O, Santesteban CG, et al.

Blood transfusion = Trasfusione del sangue 2026; (24(1)):7-18 doi:10.2450/BloodTransfus.1070.

A Neonate with FNAIT Supported by Placental Chronic Histiocytic Intervillositis and Confounded by Maternal Preeclampsia: A Case Report.

White H, Sybenga A

AJP reports 2025; (15(3)):e163-e165 doi:10.1055/a-2703-4068.

A Validation Approach for Determining Fetal Blood Groups Non-Invasively by High-Sensitive Next-Generation Sequencing.

Wienzek-Lischka S, Soelter M, Froelich A, et al.

Journal of clinical medicine 2025; (14(19)) doi:10.3390/jcm14196812.

From concept to practice: Screening for fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Pothof R, de Vos TW, Lopriore E, et al.

Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102683 doi:10.1016/j.bpobgyn.2025.102683.

Clinical management in FNAIT - navigating a complicated landscape.

Tiller H, Ahlen MT

Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102681 doi:10.1016/j.bpobgyn.2025.102681.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT): From reactive transfusion to proactive prevention.

Liu J, Liang X, Yu S

European journal of obstetrics, gynecology, and reproductive biology 2026; (321()):115046 doi:10.1016/j.ejogrb.2026.115046.